- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04906902
Acalabrutinib in CNSL
A Phase 1/2 Study of Acalabrutinib in Recurrent or Refractory Central Nervous System Lymphoma (CNSL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, dose-escalation phase 1/2 study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of Acalabrutinib in patients with recurrent or refractory CNS lymphoma (R/R CNSL).
Acalabrutinib has been studied in lab experiments and in other types of cancer, and information from these studies suggests that acalabrutinib may be beneficial for people with recurrent or refractory central nervous system lymphoma (CNSL). Acalabrutinib targets a vulnerable part of cancer cells which leads to an inhibition of the growth of cancer cells.
The U.S. Food and Drug Administration (FDA) has not approved acalabrutinib for recurrent or refractory central nervous system lymphoma (CNSL) but it has been approved for other uses.
The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
Participants will receive study treatment for up to 2 years as long as they do not have serious side effects and their disease does not get worse.
Approximately 15 to 21 participants will be enrolled in phase1 and approximately 28 patients will be enrolled Phase 2.
AstraZeneca, a pharmaceutical company, is supporting this research study by providing funding for the research study and the study drug, acalabrutinib.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Lakshmi Nayak, MD
- Phone Number: 617-632-2166
- Email: Lakshmi_Nayak@dfci.harvard.edu
Study Contact Backup
- Name: Amanda Spearman
- Phone Number: 617-632-9314
- Email: Amanda_Spearman@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Principal Investigator:
- Lakshmi Nayak, MD
-
Contact:
- Lakshmi Nayak, MD
- Phone Number: 617-632-2166
- Email: Lakshmi_Nayak@dfci.harvard.edu
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Dana Farber Cancer Institute
-
Principal Investigator:
- Lakshmi Nayak, MD
-
Contact:
- Lakshmi Nayak, MD
- Phone Number: 617-632-2166
- Email: Lakshmi_Nayak@dfci.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be able to understand and willing to sign a written informed consent document.
- Participant must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
- Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
- Participants must be at least 18 years old on day of signing informed consent.
- Participants must have a ECOG Performance Status 0-1 (see Appendix A).
- Life expectancy of > 3 months (in the opinion of the investigator).
- Participants with recurrent or refractory (R/R) must have histologically confirmed DLBCL CNS lymphoma (from brain biopsy, CSF or vitreous biopsy for PCNSL/PVRL, and includes PCNSL and SCNSL) for Phase I; R/R histologically confirmed DLBCL PCNSL (from brain biopsy only) for Phase II. Participants must have received at least 1 line of CNS-directed prior therapy. There is no maximum limit on the number of prior therapies.
- Confirmation of availability of sufficient tissue from brain biopsy for correlative studies is required prior to enrollment (for phase II only).
The following amount of archived tissue is required: At least 10 but up to 20 unstained formalin-fixed, paraffin-embedded (FFPE) slides. Histologically confirmed tissue will be required from the time of relapse or at the time of initial surgery.
- Participants must have recovered to ≤ grade 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy.
- Participants must be able to undergo MRI.
Participants must demonstrate adequate as defined below (all screening labs should be performed within 28 days of registration but before 1st dose of study drug):
Hematology
- White Blood Count (WBC) ≥ 2 K/µL
- Platelet count ≥ 100 K/µL
- Absolute Neutrophil Count ≥ 1.5 K/µL
- Hemoglobin > 9.0 g/dL or ≥ 5.6 mmol/L (Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks)
- Serum creatinine ≤1.5 x institutional ULN OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN (Creatinine clearance should be calculated per institutional standard)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤5 × ULN for participants with liver metastases)
- Total bilirubin (TBILI) ≤ 1.5 x institutional ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x institutional ULN) OR Direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN)
Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib. For male subjects with a pregnant or non-pregnant WOCBP partner, no contraception measures are required. Highly effective methods of contraception include:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable
- Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
- Bilateral tubal occlusion
- Vasectomy of a female subject's male partner (with medical assessment and confirmation of vasectomy surgical success)
- Sexual abstinence (only if refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)
Exclusion Criteria:
- Participants unable to undergo MRI brain.
- Participants with > Grade 2 intracranial hemorrhage.
- Participants with active systemic disease.
- Participants with uncontrolled intercurrent illness.
- Participants with prior exposure to BTK inhibitors
- Prior malignancy (or any other malignancy requiring active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 3 years.
- Participants who have received prior systemic anti-cancer therapy including investigational agents or radiotherapy within 4 weeks prior to dosing. OR 5 half-lives, whichever is shorter Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.
- Clinically significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or corrected QT interval (QTc) > 480 msec at screening. Note: Subjects with controlled, asymptomatic atrial fibrillation can enroll on study.
- Has difficulty with or is unable to swallow oral medication or has significant gastrointestinal disease that would limit absorption of oral medication.
- Known history of infection with HIV, prior history of PML or any active significant infection (eg, bacterial, viral, or fungal).
- Known history of hypersensitivity or anaphylaxis to acalabrutinib including active product or excipient components.
- Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease).
- Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura).
- Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.
- Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
- Prothrombin time (PT)/INR or aPTT (in the absence of lupus anticoagulant) >2x ULN.
- History of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug.
- Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
- Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B PCR positive will be excluded.
- Subjects who are hepatitis C antibody positive will need to have a negative PCR result to be eligible. Those who are hepatitis C PCR positive will be excluded.
- Breast feeding or pregnant
- Concurrent participation in another therapeutic trial.
- Liver cirrhosis categorized at Child Pugh Score C.
- Uncontrolled hypertension despite optimal medical management.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acalabrutinib Dose Escalation
Phase 1 Dose escalation will occur using a 3+3 dose escalation approach, evaluating three separate dose levels.
|
Tablet taken by mouth twice daily
Other Names:
|
Experimental: Acalabrutinib Dose Expansion
Phase 2 Participants will receive Acalabrutinib at the pre-determined dosage established in Phase 1. |
Tablet taken by mouth twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum-tolerated dose (MTD)
Time Frame: Enrollment to end of treatment up to 2 years
|
Highest dose of acalabrutinib that did not cause a dose limiting toxicity.
Dose Limiting Toxicity (DLT) rates will be summarized and 95% exact binomial confidence interval (CI) will be reported.
|
Enrollment to end of treatment up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR).
Time Frame: Enrollment to end of treatment up to 2 years
|
Clinical assessment and International Primary cns lymphoma Collaborative Group (IPCG) criteria (Abrey, 2005)
|
Enrollment to end of treatment up to 2 years
|
Duration of response (DOR)
Time Frame: Every 8 weeks up to 2 years
|
Clinical assessment and International Primary cns lymphoma Collaborative Group (IPCG) criteria (Abrey, 2005)
|
Every 8 weeks up to 2 years
|
Progression-free survival (PFS)
Time Frame: Enrollment to end of treatment up to 2 years
|
Evaluated by the Kaplan-Meier method and medians will be provided with 95% CI
|
Enrollment to end of treatment up to 2 years
|
Overall survival (OS)
Time Frame: Time from randomization (or registration) to death due to any cause, or censored at date last known alive.
|
Evaluated by the Kaplan-Meier method and medians will be provided with 95% CI
|
Time from randomization (or registration) to death due to any cause, or censored at date last known alive.
|
Treatment-related toxicity
Time Frame: Enrollment to end of treatment up to 2 years
|
Assessed by CTCAE version 5.0.
|
Enrollment to end of treatment up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lakshmi Nayak, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-059
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Central Nervous System Lymphoma
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
Curis, Inc.RecruitingRelapsed Primary Central Nervous System Lymphoma | Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy | Refractory Primary Central Nervous System LymphomaUnited States, Spain, France, Czechia, Israel, Italy, Poland
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System NeoplasmUnited States
-
Vanderbilt-Ingram Cancer CenterBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Central Nervous System Lymphoma | Central Nervous System B-Cell Non-Hodgkin Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Fred Hutchinson Cancer CenterMustang BioRecruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.; Janssen Biotech, Inc.RecruitingAdult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)United States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingRelapsed or Refractory (R/R) Primary Central Nervous System LymphomaChina
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditionsUnited States, Puerto Rico
Clinical Trials on Acalabrutinib
-
AstraZenecaAcerta Pharma, LLCCompletedPharmacokinetics | BioavailabilityUnited States
-
AstraZenecaParexelCompletedCOVID-19 | Mantle Cell LymphomaGermany
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
Acerta Pharma BVNational Institutes of Health (NIH)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Acerta Pharma BVAstraZenecaCompletedHepatic Insufficiency | Healthy Subjects | Hepatic ImpairmentUnited States
-
AstraZenecaCompletedBioequivalenceUnited States
-
AstraZenecaCompletedChronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaIndia
-
Kartos Therapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaBelgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
-
Acerta Pharma BVActive, not recruitingWaldenström Macroglobulinemia (WM)Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
-
PETHEMA FoundationActive, not recruitingChronic Lymphocytic Leukemia- Binet Staging SystemSpain